General
Preferred name
AZD-1656
Synonyms
AZD 1656 ()
AZD1656 ()
Azd1656 ()
P&D ID
PD048111
CAS
919783-22-5
Tags
available
drug candidate
Drug indication
Diabetic complication
COVID-19
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION AZD1656 activates glucokinase (GCK; P35557). AZD1656 was developed as a potential treatment for diabetes. This compound is included in AstaZeneca's Open Innovation Pharmacology Toolbox.
DESCRIPTION AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research[1][2][3].
PRICE 316
DESCRIPTION AZD1656 activates glucokinase (GCK; P35557). AZD1656 was developed as a potential treatment for diabetes. This compound is included in AstaZeneca's Open Innovation Pharmacology Toolbox. (GtoPdb)
DESCRIPTION AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes. (TargetMol Bioactive Compound Library)
Compound Sets
10
Axon Medchem Screening Library
3062
Cayman Chemical Bioactives
41839
ChEMBL Drugs
CHEMBL3219124
DrugBank
DB14810
DrugMAP
DMUE90I
Guide to Pharmacology
7701
MedChem Express Bioactive Compound Library
HY-15675
ReFrame library
Selleckchem Bioactive Compound Library
azd1656
TargetMol Bioactive Compound Library
T26712
External IDs
18
Properties
(calculated by RDKit )
Molecular Weight
478.2
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
3
cLogP
2.88
TPSA
128.66
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.49
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Glucokinase
GK activator
Carbohydrate Metabolism
Pathway
Metabolic Enzyme/Protease
Metabolism
Source data